Biogen Halts Plans to Develop Tysabri for Stroke After Phase IIb Trial Flop Post author:Sam Post published:February 6, 2018 Post category:BioPharma Natalizumab did not demonstrate improvement in clinical outcomes compared to placebo. Source: BioSpace You Might Also Like Tax Reform: A War on Life Sciences Innovation December 11, 2017 PRA Health Sciences Announces The Center For Pediatric Clinical Development May 3, 2017 Why This Connecticut Biotech Could be a $1M Opportunity for Investors January 23, 2018
